Acute effect of tumor necrosis factor-α is minimal on mechanics but significant on energetics in blood-perfused canine left ventricles

Critical Care Medicine

Volumn 27, Issue 1, 1999, Pages 168-176

  Miyano, Hiroshi ^a   Shishido, Toshiaki ^a   Kawada, Toru ^a   Miyashita, Hiroshi ^a   Sato, Takayuki ^a   Sugimachi, Masaru ^a   Sunagawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Calcium handling; Canine isolated heart; Excitation contraction coupling; Inotropic effect; Left ventricular contractility; Myocardial oxygen consumption; Septic shock; Tumor necrosis factor

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CATECHOLAMINE RELEASE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; HEART LEFT VENTRICLE; HEART PERFUSION; IMMUNOMODULATION; IMMUNOPATHOLOGY; MUSCLE CONTRACTILITY; NONHUMAN; OXYGEN CONSUMPTION; PRESSURE VOLUME CURVE; PRIORITY JOURNAL;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CORONARY CIRCULATION; CRITICAL CARE; DOGS; FEMALE; MALE; OXYGEN; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032922274     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199901000-00046     Document Type: Article

References (50)

1. 1. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of Gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937
2. 2. Nishikawa Y, Mathison J, Lew WY: Serum tumor necrosis factor-α does not mediate endotoxin-induced myocardial depression in rabbits. Am J Physiol 1996; 270:H485-H491
3. 3. Kapadia S, Torre-Amione G, Yokoyama T, et al: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am J Physiol 1995; 268:H517-H525
4. 4. Blick M, Sherwin SA, Rosenblum M, et al: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47:2986-2989
5. 5. Vincent JL, Bakker J, Marécaux G, et al: Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 1992; 101:810-815
6. 6. Ellrodt AG, Riedinger MS, Kimchi A, et al: Left ventricular performance in septic shock: Reversible segmental and global abnormalities. Am Heart J 1985; 110:402-409
7. 7. Parker MM, McCarthy KE, Ognibene FP, et al: Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97:126-131
8. 8. Kinkel MS, Oddis CV, Jacob TD, et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257:387-389
9. 9. Yokoyama T, Vaca L, Rossen RD, et al: Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993; 92:2303-2312
10. 2+], and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996; 271:H1449-H1455
11. 11. Oral H, Dorn GW II, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem 1997; 272:4836-4842
12. 12. Eichenholz PW, Eichacker PQ, Hoffman WD, et al: Tumor necrosis factor challenges in canines: Patterns of cardiovascular dysfunction. Am J Physiol 1992; 263:H668-H675
13. 13. Pagani FD, Baker LS, Hsi C, et al: Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest 1992; 90:389-398
14. 14. Walley KR, Hebert PC, Wakai Y, et al: Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol 1994; 76:1060-1067
15. 15. Murray DR, Freeman GL: Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996; 78:154-160
16. 2+ transients. FEBS Lett 1995; 376:24-30
17. 17. Suga H: Ventricular energetics. Physiol Rev 1990; 70:247-277
18. 18. Ohgoshi Y, Goto Y, Futaki S, et al: Increased oxygen cost of contractility in stunned myocardium of dog. Circ Res 1991; 69:975-988
19. + exchange system. Circ Res 1994; 74:794-805
20. 2 saturation, and hemoglobin content. Am J Physiol 1989; 257:H1712-H1716
21. 21. Sagawa K, Maughan L, Suga H, et al: Cardiac Contraction and the Pressure-Volume Relationship. New York, Oxford University Press, 1988, pp 42-170
22. 22. Glantz SA: Primer of Biostatistics. Third Edition. New York, McGraw-Hill, 1992
23. 23. Torre-Amione G, Kapadia S, Lee J, et al: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92:1487-1493
24. 24. Mitaka C, Hirata Y, Ichikawa K, et al: Effects of TNF-α on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. Am J Physiol 1994; 267:H1530-H1536
25. 25. Oddis CV, Finkel MS: Cytokines and nitric oxide synthase inhibitor as mediators of adrenergic refractoriness in cardiac myocytes. Eur J Pharmacol 1997; 320:167-174
26. 26. Boillot A, Massol J, Maupoil V, et al: Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: Reversal by an anti-tumor necrosis factor-α monoclonal antibody. Crit Care Med 1997; 25:504-511
27. 27. Brenner DA, O'Hara M, Angel P, at al: Prolonged activation of jun and collagenase genes by tumor necrosis factor-α. Nature 1989; 337:661-663
28. 28. Zhang YH, Lin JX, Yip YK, et al: Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: Role in the induction of interleukin 6. Proc Natl Acad Sci U S A 1988; 85:6802-6805
29. 29. Vilcek J, Lee TH: Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991; 266:7313-7316
30. 30. Cunnion RE, Schaer GL, Parker MM, et al: The coronary circulation in human septic shock. Circulation 1986; 73:637-644
31. 31. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75:533-541
32. 32. Balligand JL, Kelly RA, Marsden PA, et al: Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 1993; 90:347-351
33. 33. Brady AJ, Poole-wilson PA, Harding SE, et al: Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992; 263:H1963-H1966
34. 34. Herbertson MJ, Werner HA, Walley KR: Nitric oxide synthase inhibition partially prevents decreased LV contractility during endotoxemia. Am J Physiol 1996; 270:H1979-H1984
35. 35. Mohan P, Brutsaert DL, Paulus WJ, et al: Myocardial contractile response to nitric oxide and cGMP. Circulation 1996; 93:1223-1229
36. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993; 15: 26286-26295
37. 37. Kirstein M, Rivet-Bastide M, Hatem S, et al: Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995; 95: 794-802
38. 2+ in intact cardiac myocytes. Circ Res 1994; 74: 970-978
39. 39. Yoshizumi M, Perrella MA, Burnett JC Jr, et al: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73:205-209
40. 40. Rosenkranz-Weiss P, Sessa WC, Milstien S, et al: Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994; 93: 2236-2243
41. 2 consumption and systolic pressure-volume area or force-time integral. Circ Res 1990; 66:999-1011
42. 42. Cooper DJ, Thompson CR, Walley KR, et al: Histamine decreases left ventricular contractility in normal human subjects. J Appl Physiol 1992; 73: 2530-2537
43. 43. Maughan WL, Sunagawa K, Burkhoff D, et al: Effect of heart rate on the canine end-systolic pressure-volume relationship. Circulation 1985; 72: 654-659
44. 44. Wang DY, Chae SW, Gong QY, et al: Role of aiNa in positive force-frequency staircase in guinea pig papillary muscle. Am J Physiol 1988; 255:C798-C807
45. 45. Dofferhoff AS, Bom VJ, deVries-Hospers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20:185-192
46. 46. Damas P, Canivet JL, de Groote D, et al: Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25: 405-412
47. 47. Giroir BP, Johnson JH, Brown T, et al: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992; 90:693-698
48. 48. Kapadia S, Lee J, Torre-Amione G, et al: Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96:1042-1052
49. 49. Waage A, Halstensen A, Espevik T: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 14:355-357
50. 50. Calandra T, Baumgartner JD, Grau GE, the Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis 1990; 161:982-987